Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using
the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation
therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory
(R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral
T-cell lymphoma (PTCL) in 1st remission.